India Regulator Caps Prices Of Ranbaxy ED Drug, Antibiotic
This article was originally published in PharmAsia News
India's drug price regulator has imposed a cap on the cost of generics of an erectile dysfunction drug and an antibiotic, both made by Ranbaxy Laboratories. The National Pharmaceutical Pricing Authority capped the price of Caverta, Ranbaxy's version of Pfizer's Viagra (sildenafil citrate) and its Cilanem antibiotic injection version of Merck's Primaxin (cilastatin sodium, imipenem). Ranbaxy has asked for a review of the NPPA ruling at the ministerial level, arguing the agency is inconsistent in its pricing decisions for similar drugs. (Click here for more
You may also be interested in...
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Early Research Suggests Wearables Can Spot Early Signs Of COVID-19; Fitbit Receives $2.5m Army Award
A consortium of researchers, including Fitbit, are developing algorithms to spot COVID-19 before people become ill.